Boltz raises $110M Series A led by Bessemer for AI drug discovery models
The London startup, spun out of MIT, says it will spend the money on compute, data and hiring. It has announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb.
What happened
Boltz is a startup that builds AI models to help find new medicines. Its software predicts how a drug candidate fits onto a protein, which is the target in the body. It also suggests new molecules that could bind to that target. The company has now raised $110 million from investors.
Why it matters to you
Drug research is slow and costly, and tools that help scientists pick which candidates to test in labs could cut some of that work. Drug makers are already working with the company.
The takeaway
An AI drug discovery startup raised $110 million and plans to build bigger and better models.
What it means for you
Open-source Boltz models and a platform API give teams two ways to access structure and binding prediction tools.
Pharma and biotech teams can use Boltz models to help design candidates and choose which to test in labs.
Boltz raised a $110M Series A led by Bessemer, with a16z, Amplify, Zetta, Obvious Ventures, Greycroft, F-Prime, Hummingbird, Benchling and Nvidia named as investors, Tech.eu reports.